Technical Analysis for GLMD - Galmed Pharmaceuticals Ltd.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 0.37 | 1.65% | 0.01 |
GLMD closed up 1.65 percent on Friday, May 31, 2024, on 24 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| 20 DMA Resistance | Bearish | 1.65% | |
| 50 DMA Resistance | Bearish | 1.65% | |
| Earnings Movers | Other | 1.65% | |
| BB Squeeze Ended | Range Expansion | 1.65% |
| Alert | Time |
|---|---|
| Gap Up Closed | 1 day ago |
| Gap Up Partially Closed | 1 day ago |
| 50 DMA Resistance | 1 day ago |
| 10 DMA Resistance | 1 day ago |
| Possible NR7 | 1 day ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/30/2024
GalMed Medical Research Ltd. researches and develops proprietary drugs for the treatment of lipid metabolism related diseases. The company has developed a series of proprietary fatty acid bile-acid conjugates (FABACs) which selectively inhibit the enzyme Stearoyl-CoA Desaturase (SCD1), a key regulator in lipid metabolism. It's flagship clinical compound Aramchol (arachidyl amido cholanoic acid), has the potential to modify several of the key disorders related to lipid metabolism, including fatty liver, gallstones, diabetes, hyperlipidemia, cancer, and alzheimer's disease. The company is based in Tel Aviv, Israel. GalMed Medical Research Ltd. operates as a subsidiary of Galmed International Ltd.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Acid Diabetes Alzheimer's Disease Lipid Medical Research Metabolism Hepatology Fatty Acids Fatty Liver Hyperlipidemia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Acid Diabetes Alzheimer's Disease Lipid Medical Research Metabolism Hepatology Fatty Acids Fatty Liver Hyperlipidemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 5.47 |
| 52 Week Low | 0.2601 |
| Average Volume | 138,123 |
| 200-Day Moving Average | 0.44 |
| 50-Day Moving Average | 0.37 |
| 20-Day Moving Average | 0.39 |
| 10-Day Moving Average | 0.38 |
| Average True Range | 0.03 |
| RSI (14) | 45.36 |
| ADX | 13.74 |
| +DI | 15.07 |
| -DI | 13.22 |
| Chandelier Exit (Long, 3 ATRs) | 0.34 |
| Chandelier Exit (Short, 3 ATRs) | 0.44 |
| Upper Bollinger Bands | 0.42 |
| Lower Bollinger Band | 0.36 |
| Percent B (%b) | 0.16 |
| BandWidth | 15.85 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.0047 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.41 | ||||
| Resistance 3 (R3) | 0.41 | 0.40 | 0.40 | ||
| Resistance 2 (R2) | 0.40 | 0.39 | 0.40 | 0.40 | |
| Resistance 1 (R1) | 0.39 | 0.38 | 0.38 | 0.38 | 0.40 |
| Pivot Point | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 |
| Support 1 (S1) | 0.36 | 0.36 | 0.35 | 0.36 | 0.34 |
| Support 2 (S2) | 0.35 | 0.36 | 0.35 | 0.34 | |
| Support 3 (S3) | 0.33 | 0.35 | 0.34 | ||
| Support 4 (S4) | 0.33 |
